Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2
- PMID: 23776246
- PMCID: PMC3704038
- DOI: 10.1073/pnas.1305321110
Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2
Abstract
Oxaliplatin is an integral component of colorectal cancer therapy, but its clinical use is associated with a dose-limiting peripheral neurotoxicity. We found that the organic cation transporter 2 (OCT2) is expressed on dorsal root ganglia cells within the nervous system where oxaliplatin is known to accumulate. Cellular uptake of oxaliplatin was increased by 16- to 35-fold in cells overexpressing mouse Oct2 or human OCT2, and this process was associated with increased DNA platination and oxaliplatin-induced cytotoxicity. Furthermore, genetic or pharmacologic knockout of Oct2 protected mice from hypersensitivity to cold or mechanical-induced allodynia, which are established tests to assess acute oxaliplatin-induced neurotoxicity. These findings provide a rationale for the development of targeted approaches to mitigate this debilitating toxicity.
Keywords: chemotherapy; neuropathy; solute carriers.
Conflict of interest statement
The authors declare no conflict of interest.
Figures






Similar articles
-
L-tetrahydropalmatine reduces oxaliplatin accumulation in the dorsal root ganglion and mitochondria through selectively inhibiting the transporter-mediated uptake thereby attenuates peripheral neurotoxicity.Toxicology. 2021 Jul;459:152853. doi: 10.1016/j.tox.2021.152853. Epub 2021 Jul 9. Toxicology. 2021. PMID: 34252480
-
Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice.J Clin Invest. 2020 Sep 1;130(9):4601-4606. doi: 10.1172/JCI136796. J Clin Invest. 2020. PMID: 32484793 Free PMC article.
-
Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons.J Pharmacol Exp Ther. 2011 Aug;338(2):537-47. doi: 10.1124/jpet.111.181297. Epub 2011 May 23. J Pharmacol Exp Ther. 2011. PMID: 21606177
-
Platinum accumulation in oxaliplatin-induced peripheral neuropathy.J Peripher Nerv Syst. 2021 Mar;26(1):35-42. doi: 10.1111/jns.12432. Epub 2021 Jan 27. J Peripher Nerv Syst. 2021. PMID: 33462873 Free PMC article. Review.
-
Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests.Anticancer Drugs. 2013 Nov;24(10):1069-78. doi: 10.1097/CAD.0000000000000002. Anticancer Drugs. 2013. PMID: 24025562 Review.
Cited by
-
Influence of YES1 Kinase and Tyrosine Phosphorylation on the Activity of OCT1.Front Pharmacol. 2021 Mar 8;12:644342. doi: 10.3389/fphar.2021.644342. eCollection 2021. Front Pharmacol. 2021. PMID: 33790797 Free PMC article.
-
Pathological Mechanisms and Preventive Strategies of Oxaliplatin-Induced Peripheral Neuropathy.Front Pain Res (Lausanne). 2021 Dec 8;2:804260. doi: 10.3389/fpain.2021.804260. eCollection 2021. Front Pain Res (Lausanne). 2021. PMID: 35295491 Free PMC article. Review.
-
Preventive Efficacy and Safety of Yiqi-Wenjing-Fang Granules on Oxaliplatin-Induced Peripheral Neuropathy: A Protocol for a Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.Evid Based Complement Alternat Med. 2021 Sep 29;2021:5551568. doi: 10.1155/2021/5551568. eCollection 2021. Evid Based Complement Alternat Med. 2021. PMID: 34630609 Free PMC article.
-
Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).Clin Cancer Res. 2014 Feb 15;20(4):985-94. doi: 10.1158/1078-0432.CCR-13-1999. Epub 2013 Dec 18. Clin Cancer Res. 2014. PMID: 24352644 Free PMC article.
-
Uptake carriers and oncology drug safety.Drug Metab Dispos. 2014 Apr;42(4):611-22. doi: 10.1124/dmd.113.055806. Epub 2013 Dec 30. Drug Metab Dispos. 2014. PMID: 24378324 Free PMC article. Review.
References
-
- Cascinu S, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2002;20(16):3478–3483. - PubMed
-
- Gamelin L, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004;10(12 Pt 1):4055–4061. - PubMed
-
- Ishibashi K, Okada N, Miyazaki T, Sano M, Ishida H. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: A prospective randomized study. Int J Clin Oncol. 2010;15(1):82–87. - PubMed
-
- Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol. 2007;25(25):4028–4029. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials